Monitoring patients' hydroxychloroquine blood levels can predict their clotting risk

The antimalarial drug hydroxychloroquine is frequently prescribed to treat symptoms of the autoimmune disease lupus. In addition to decreasing disease flares, the drug can also prevent blood clots, which are a major problem in individuals with lupus.

A new study in Arthritis & Rheumatology shows that monitoring patients' blood levels of hydroxychloroquine can predict their clotting risk.

In 739 patients, clotting occurred in 38 patients (5.1%). Average hydroxychloroquine blood levels were lower in patients who developed clots, and clotting rates were reduced by 12% for every 200 ng/mL increase in the most recent hydroxychloroquine blood level.

The finding may help clinicians determine the optimal dosing of hydroxychloroquine in patients with lupus.

Hydroxychloroquine blood levels can be used to monitor adherence, benefits, and risks in lupus."

Michelle Petri, MD, MPH, Study Lead Author, Johns Hopkins University School of Medicine

Journal reference:

Englund, T. R., et al. (2020) Rise and Fall: Hydroxychloroquine and COVID‐19 Global Trends: Interest, Political Influence, and Potential Implications. Arthritis & Rheumatology.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
You might also like...
The impact of sleep fragmentation on the clonal diversity of immune cells and the genetic aging of the hematopoietic system